Three patients (9.1%) permanently discontinued treatment due to TRAEs: one patient due to grade 3 anemia; 1 patient due to grade 3 alanine aminotransferase (ALT) increased and aspartate aminotransferase (AST) increased; and 1 patient died due to dyspnea, hemolysis, and thrombocytopenia. This evidence concerns the gene GPT and Thrombocytopenia.